Neuroepigenetic Mechanisms of Action of Ultrashort Peptides in Alzheimer’s Disease
Review of earlier studies · 2022
- What was studied
- Review of earlier research
- Main finding
- Develops hypotheses connecting short peptides with gene regulation and neurodegenerative processes. Hypotheses are retained as mechanistic proposals, not clinical conclusions.
Study data at a glance
- Participants or experimental model
- Review of earlier research
- Reported results
- Develops hypotheses connecting short peptides with gene regulation and neurodegenerative processes. Hypotheses are retained as mechanistic proposals, not clinical conclusions.
Study limitations and source details
Study limitations
- Source-linked does not mean a completed risk-of-bias review.
- A review is not an independent clinical replication; proposed mechanisms do not establish efficacy or safety.
Source details
Source scope and bibliographic record checked; see the original experiments for methods and results.
Sources checked
Citation
Author list available on linked original paper. Neuroepigenetic Mechanisms of Action of Ultrashort Peptides in Alzheimer’s Disease International Journal of Molecular Sciences 23(8):4259
Study source ↗ · DOI 10.3390/ijms23084259 · Bibliography entry · Link to this summary
Related compounds
Pinealon
A synthetic tripeptide, Glu–Asp–Arg (EDR). Researchers have examined its effects in neuronal aging models and measured functional outcomes in human performance studies.
KED
A three-amino-acid peptide (Lys–Glu–Asp) studied in vascular and nerve-cell research and catalogued as Vesugen.
Epitalon
A synthetic tetrapeptide, Ala–Glu–Asp–Gly (AEDG, also called Epithalon), developed from pineal-gland research. Human studies examined melatonin secretion, circadian markers and retinal function.